NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) from September 23, 2020 through November 16, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for GoodRx Holdings, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical busine
IMPORTANT JAN 26 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Fortress Biotech, Inc - FBIO
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) from December 11, 2019 through October 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Fortress Biotech, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you wish to serve as lead plaintiff, you must move the
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI) from March 15, 2019 through November 27, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Kandi Technologies Group, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms-length relationship with Kandi; the majority of Kandi’s sales in the past year had been to undisclosed related pa
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Triterras, Inc. f/k/a Netfin Acquisition Corp. (NASDAQ: TRIT, TRITW) from August 20, 2020 through December 16, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Triterras, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: the extent to which the Company’s revenue growth relied on Triterras’ relationship with Rhodium Resources Pte. Ltd. (“Rhodium”) to refer users to the Kratos platform; that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; th
vimarsana © 2020. All Rights Reserved.